ClinicalTrials.gg
TerminatedNCT03258814Treat & TrainUpdated Oct 2, 2019Results posted

A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

An observational study in Axial Spondyloarthritis, sponsored by AbbVie. Terminated at 6 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-10-02.

Sponsored by AbbVie · Observational

How we know

Why this study was terminated
Low or No Enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
17
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Axial Spondyloarthritis with a site in Germany — 6 open to participants now, 9 under way, 1 of them phase 3. Axial Spondyloarthritis · Germany.

Started
2017
with 3 others
Observational
8 of 30
1 open now
Registered
13th of 30
by date
Lead sponsor
3 of 30
AbbVie

Among the 30 studies in Axial Spondyloarthritis with a site in Germany, this one is one of 4 that started in 2017, is one of 8 observational ones, and was the 13th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

6 of the 30 studies in Axial Spondyloarthritis with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Axial Spondyloarthritis with a site in Germany, or all of them as a file.
02

Study summary

This study is a non-interventional, longitudinal and non-confirmatory study to compare an active supervised training (AST) with standard of care (SOC) physiotherapy in patients with axial spondyloarthritis and stable response to adalimumab (HUMIRA®) with respect to health-related outcomes. The primary objective is the improvement in spinal mobility after a 6 month training program.

Read the detailed description

Treatment of axSpA patients with adalimumab (HUMIRA®) was according to the local adalimumab product label and local standard of care. AxSpA patients who responded to newly initialized adalimumab treatment based on physicians' decision, and who were eligible for active physiotherapy were enrolled in the study. Although this was a non-interventional study, participants were randomly assigned to receive either active supervised and standardized training physiotherapy or standard of care physiotherapy in order to provide adequate numbers of participants in each comparison group.

Participants who consented to participate in the study were observed for up to 12 months from Baseline (defined as the Randomization visit where participants were assigned to one of the two physiotherapy options).

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • axial spondyloarthritis
  • active supervised training
  • physical training
  • adalimumab
  • spinal mobility
  • physiotherapy
  • physical function
  • health-related quality of life
  • pain
  • disease activity
  • psychosocial risk factors
  • workability
  • Bath Ankylosing Spondylitis Metrology Index (BASMI)
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants with axial spondyloarthritis who received Humira® per local product label at rheumatology centers in Germany.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with axial spondyloarthritis (axSpA) (either ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA)), fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification, aged at least 18 years
  • Prescription of Humira® (adalimumab) for treating axSpA according to the local product label
  • Eligibility for active physiotherapy according to the rheumatologist and physiotherapist
  • Participants must have signed written before starting any study related assessments or procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants with total spinal ankylosis based on the investigators' assessments of available radiographs
  • Participants who are not eligible for active supervised training or active physiotherapy at the discretion of the rheumatologist and/or the physiotherapist
  • Participants with poorly controlled medical condition(s), which in the opinion of the investigator, would put the participant at risk by participation in the protocol
  • Any prior treatment with a biologic disease-modifying antirheumatic drugs (DMARD) is prohibited.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
17 participants (actual)

Groups and cohorts

  • Active Supervised Training (AST)

    Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).

    Behavioral: Active Supervised Training (AST)

  • Standard of Care (SOC) Physiotherapy

    Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.

    Behavioral: Standard of Care (SOC) Physiotherapy

Interventions

  • BehavioralActive Supervised Training (AST)

    The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.

  • BehavioralStandard of Care (SOC) Physiotherapy

    Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.

06

What researchers measure

Primary outcomes

  1. Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 6

    BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3

    BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis.

    Time frame: Baseline and Month 3

  2. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, each on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher score indicating more limitations.

    Time frame: Baseline and Month 3

  3. Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)

    The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.

    Time frame: Baseline and Month 3

  4. Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.

    Time frame: Baseline and Month 3

  5. Percentage of Participants Achieving a BASDAI 50 Response

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.

    Time frame: Month 3

  6. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

    Time frame: Baseline and Month 3

  7. Percentage of Participants With ASDAS Inactive Disease

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease, defined as ASDAS \< 1.3, is reported.

    Time frame: Month 3

  8. Percentage of Participants With ASDAS Low Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity, defined as ASDAS \< 2.1, is reported.

    Time frame: Month 3

  9. Percentage of Participants With ASDAS Moderate Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity, defined as an ASDAS ≥ 1.3 to \< 2.1, is reported.

    Time frame: Month 3

  10. Percentage of Participants With ASDAS High Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with high disease activity, defined as an ASDAS ≥ 2.1 to \< 3.5, is reported.

    Time frame: Month 3

  11. Percentage of Participants With ASDAS Very High Disease Activity

    ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with very high disease activity, defined as an ASDAS ≥ 3.5, is reported.

    Time frame: Month 3

  12. Percentage of Participants Achieving ASDAS Major Improvement

    ASDAS Major Improvement is defined as a change from Baseline ≥ 2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

    Time frame: Baseline and Month 3

  13. Percentage of Participants Achieving ASDAS Clinically Important Improvement

    ASDAS clinically important improvement is defined as a change from Baseline ≥ 1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

    Time frame: Baseline and Month 3

  14. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

    ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Month 3

  15. Percentage of Participants Achieving an ASAS 40 Response

    ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Baseline and Month 3

  16. Percentage of Participants Achieving ASAS Partial Remission

    ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Time frame: Month 3

  17. Change From Baseline in Patient's Global Assessment of Pain

    The patient's global assessment of pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).

    Time frame: Baseline and Month 3

  18. Change From Baseline in Patient's Assessment of Total Back Pain

    The patient's assessment of total back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).

    Time frame: Baseline and Month 3

  19. Change From Baseline in Patient's Assessment of Nocturnal Back Pain

    The patient's assessment of nocturnal back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).

    Time frame: Baseline and Month 3

  20. Change From Baseline in Modified Work Ability Index (WAI)

    This is used to assess participant's work ability.

    Time frame: Baseline and Month 3

  21. Change From Baseline in Fatigue

    Fatigue was assessed as Question 1 of the BASDAI, on a NRS from 0 (none) to 10 (very severe).

    Time frame: Baseline and Month 3

  22. Change From Baseline in Severity and Duration of Morning Stiffness

    Morning stiffness was measured as the mean of the 2 morning stiffness-related BASDAI NRS scores: Question 5: Level of morning stiffness assessed by the patient on a scale from 0 (none) to 10 (very severe), and Question 6: Duration of morning stiffness assessed by the patient on a scale from 0 (0 hours) to 10 (2 hours or more duration).

    Time frame: Baseline and Month 3

  23. Change From Baseline in Fear-Avoidance Belief Questionnaire Score (FABQ)

    The FABQ measures patients' fear of pain and consequent avoidance of physical activity because of their fear. The questionnaire consists of 16 items in which a patient rates their agreement with each statement on a 7-point Likert scale, where 0 = completely disagree, 6 = completely agree. There is a maximum score of 96. A higher score indicates more strongly held fear avoidance beliefs.

    Time frame: Baseline and Month 3

07

Results

Posted Oct 2, 2019
Limitations and caveats
Due to early termination of the study, no interpretations or conclusions can be made based on the results.

Participant flow

This study enrolled participants with axial spondyloarthritis (AS) at 7 study sites in Germany. Eligible participants were receiving treatment with adalimumab (HUMIRA®) based on therapist's decision and local label requirements, must have had a response to adalimumab and have been eligible for active physiotherapy.

Participant flow — Overall Study
MilestoneActive Supervised Training (AST)Standard of Care (SOC) PhysiotherapyNot Randomized
Started4310
Completed000
Not completed4310
Withdrew: Early termination4310

Outcome measures

PrimaryChange Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 6

BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis

Time frame:
Baseline and Month 6

No measurements were reported for this outcome.

SecondaryChange Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3

BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis.

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 31.1 ± 0.4—
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, each on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher score indicating more limitations.

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)-0.1 ± 0.1—
SecondaryChange From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)

The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)0.5 ± 0.7—
SecondaryChange From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-0.4 ± 0.2—
SecondaryPercentage of Participants Achieving a BASDAI 50 Response

The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a BASDAI 50 Response
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving a BASDAI 50 Response0.0—
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-0.3 ± 0.1—
SecondaryPercentage of Participants With ASDAS Inactive Disease

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease, defined as ASDAS \< 1.3, is reported.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Inactive Disease
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants With ASDAS Inactive Disease50.0—
SecondaryPercentage of Participants With ASDAS Low Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity, defined as ASDAS \< 2.1, is reported.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Low Disease Activity
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants With ASDAS Low Disease Activity50.0—
SecondaryPercentage of Participants With ASDAS Moderate Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity, defined as an ASDAS ≥ 1.3 to \< 2.1, is reported.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Moderate Disease Activity
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants With ASDAS Moderate Disease Activity0.0—
SecondaryPercentage of Participants With ASDAS High Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with high disease activity, defined as an ASDAS ≥ 2.1 to \< 3.5, is reported.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS High Disease Activity
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants With ASDAS High Disease Activity50.0—
SecondaryPercentage of Participants With ASDAS Very High Disease Activity

ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity." The percentage of participants with very high disease activity, defined as an ASDAS ≥ 3.5, is reported.

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With ASDAS Very High Disease Activity
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants With ASDAS Very High Disease Activity0.0—
SecondaryPercentage of Participants Achieving ASDAS Major Improvement

ASDAS Major Improvement is defined as a change from Baseline ≥ 2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

Time frame:
Baseline and Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS Major Improvement
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving ASDAS Major Improvement0.0—
SecondaryPercentage of Participants Achieving ASDAS Clinically Important Improvement

ASDAS clinically important improvement is defined as a change from Baseline ≥ 1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and ≥ 3.5 for "very high disease activity."

Time frame:
Baseline and Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASDAS Clinically Important Improvement
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving ASDAS Clinically Important Improvement0.0—
SecondaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response

ASAS20 response was defined as improvement of ≥ 20% relative to Baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response0.0—
SecondaryPercentage of Participants Achieving an ASAS 40 Response

ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Baseline and Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ASAS 40 Response
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving an ASAS 40 Response0.0—
SecondaryPercentage of Participants Achieving ASAS Partial Remission

ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

Time frame:
Month 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ASAS Partial Remission
percentage of participantsActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Percentage of Participants Achieving ASAS Partial Remission0.0—
SecondaryChange From Baseline in Patient's Global Assessment of Pain

The patient's global assessment of pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Patient's Global Assessment of Pain
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Patient's Global Assessment of Pain-0.5 ± 0.7—
SecondaryChange From Baseline in Patient's Assessment of Total Back Pain

The patient's assessment of total back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Patient's Assessment of Total Back Pain
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Patient's Assessment of Total Back Pain0.5 ± 0.7—
SecondaryChange From Baseline in Patient's Assessment of Nocturnal Back Pain

The patient's assessment of nocturnal back pain was assessed on a NRS from 0 (no pain) to 10 (most severe pain).

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Patient's Assessment of Nocturnal Back Pain
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Patient's Assessment of Nocturnal Back Pain-0.5 ± 0.7—
SecondaryChange From Baseline in Modified Work Ability Index (WAI)

This is used to assess participant's work ability.

Time frame:
Baseline and Month 3

No measurements were reported for this outcome.

SecondaryChange From Baseline in Fatigue

Fatigue was assessed as Question 1 of the BASDAI, on a NRS from 0 (none) to 10 (very severe).

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Fatigue
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Fatigue-0.5 ± 0.7—
SecondaryChange From Baseline in Severity and Duration of Morning Stiffness

Morning stiffness was measured as the mean of the 2 morning stiffness-related BASDAI NRS scores: Question 5: Level of morning stiffness assessed by the patient on a scale from 0 (none) to 10 (very severe), and Question 6: Duration of morning stiffness assessed by the patient on a scale from 0 (0 hours) to 10 (2 hours or more duration).

Time frame:
Baseline and Month 3
Reported as:
Mean · scores on a scale
Change From Baseline in Severity and Duration of Morning Stiffness
scores on a scaleActive Supervised Training (AST)Standard of Care (SOC) Physiotherapy
Change From Baseline in Severity and Duration of Morning Stiffness-1.5 ± 0.7—
SecondaryChange From Baseline in Fear-Avoidance Belief Questionnaire Score (FABQ)

The FABQ measures patients' fear of pain and consequent avoidance of physical activity because of their fear. The questionnaire consists of 16 items in which a patient rates their agreement with each statement on a 7-point Likert scale, where 0 = completely disagree, 6 = completely agree. There is a maximum score of 96. A higher score indicates more strongly held fear avoidance beliefs.

Time frame:
Baseline and Month 3

No measurements were reported for this outcome.

Adverse events

Collected over Up to 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Supervised Training (AST)0/4 (0%)0/4 (0%)2/4 (50%)
Standard of Care (SOC) Physiotherapy0/3 (0%)0/3 (0%)2/3 (66.7%)
Not Randomized0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Most frequent other events
EventActive Supervised Training (AST)Standard of Care (SOC) PhysiotherapyNot Randomized
Pulpitis dentalInfections and infestations0/41/30/10
Urinary tract infectionInfections and infestations0/41/30/10
Road traffic accidentInjury, poisoning and procedural complications0/41/30/10
Bone lesionMusculoskeletal and connective tissue disorders0/41/30/10
Back painMusculoskeletal and connective tissue disorders1/40/30/10
PsoriasisSkin and subcutaneous tissue disorders1/40/30/10
Axial spondyloarthritisMusculoskeletal and connective tissue disorders0/40/31/10

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Active Supervised Training (AST)Standard of Care (SOC) PhysiotherapyTotal
Median52 (37 to 66)31 (30 to 43)38 (30 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Active Supervised Training (AST)Standard of Care (SOC) PhysiotherapyTotal
Female213
Male224
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Active Supervised Training (AST)Standard of Care (SOC) PhysiotherapyTotal
Count of participants——0
Bath Ankylosing Spondylitis Metrology Index (BASMI)
Bath Ankylosing Spondylitis Metrology Index (BASMI)(units on a scale)Active Supervised Training (AST)Standard of Care (SOC) PhysiotherapyTotal
Mean2.9 ± 3.32.2 ± 0.82.6 ± 2.0
08

Study locations

6 sites
  • Rheumahaus Studien GbR, Potsdam, DE /ID# 164494
    Potsdam, Brandenburg 14467, Germany
  • MVZ Wittenbergplatz PP Orthos /ID# 204802
    Berlin, 10787, Germany
  • Rheumapraxis /ID# 164461
    Halle, 06128, Germany
  • Praxis Ortho DE /ID# 204149
    Hamburg, 22415, Germany
  • Praxis internistische Rheumato /ID# 164463
    Leipzig, 04129, Germany
  • Krankenhaus St. Josef /ID# 164501
    Wuppertal, 42105, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Sep 2018, 9 months.

Results were first posted in Oct 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Aug 23, 2017
StartActual
Dec 8, 2017
Primary completionActual
Sep 14, 2018
CompletionActual
Sep 14, 2018
Results first posted
Oct 2, 2019
Last update
Oct 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03258814
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 23, 2017
Start date
Dec 8, 2017
Primary completion
Sep 14, 2018
Completion
Sep 14, 2018
Results posted
Oct 2, 2019
Last update
Oct 2, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion